Pharmatek Laboratories, Inc. has announced the addition of cytotoxic and high-potent drug development capabilities to its pharmaceutical chemistry development services.
Cytotoxic and high-potent services include analytical method development, preformulation testing, formulation development, manufacturing for early phase clinical trials, release testing, and stability testing and storage.
“This expansion was driven by an increase in demand for cytotoxic and high-potent drug development and manufacturing outsourcing among our clients,” said Dr. Jeffrey Bibbs, CEO of Pharmatek. “This added capability enables us to provide a broader level of services to our clients with cytotoxic and high-potent candidates.”
Pharmatek’s cytotoxic and high-potent development services will be carried out in a separate dedicated facility. Manufacturing capability includes two validated and licensed class 100,000 high-containment suites designed with barrier technology for cGMP manufacturing of final form drug products.
Dedicated HVAC and HEPA filtration systems ensure product containment within the suites. Personnel are protected through strict gowning and control procedures to ensure employee safety while working in the suites.
“Pharmatek has been a valued resource for the development and manufacturing of non-potent drugs for more than eight years,” said Timothy Scott, president of Pharmatek. “This investment positions Pharmatek to become a leading cytotoxic and high-potent drug development service provider.”